---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-047925"
form_type: "8-K/A"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:17:37.613421+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio amends CEO Josh Lehrer's separation agreement with consulting and equity acceleration terms

## Summary
- Separation agreement dated Sept 7, 2023 provides Tier 1 severance benefits under Executive Severance Plan.
- Lehrer to serve as consultant for up to 12 months or until a Strategic Transaction closes.
- Equity awards continue vesting during consulting; acceleration if Strategic Transaction within 6 months.
- If Strategic Transaction within 3 months, Lehrer receives enhanced benefits as if termination during Change in Control.
- Strategic Transaction defined broadly: merger, sale, reverse merger, or Sale Event under 2021 Stock Plan.

## SEC filing metadata
- accession: 0000950170-23-047925
- form_type: 8-K/A
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/0000950170-23-047925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/grph-20230818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-047925
- JSON: https://secwatch.observer/filing/0000950170-23-047925.json
- Plain text: https://secwatch.observer/filing/0000950170-23-047925.txt

## Key facts
- Executive change
  Josh Lehrer departed as President, Chief Executive Officer at LENZ Therapeutics, Inc..
  - Action: separated
  - Role: President, Chief Executive Officer
  source text: effective as of August 21, 2023 (the “Termination Date”), Josh Lehrer, M.D., the former President, Chief Executive Officer and member of the Board of Directors of Graphite Bio, Inc. (the “Company”), separated from his employment and all officer and director positions with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023047925/0000950170-23-047925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.